These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 19901556)
1. The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Escuin D; Burke PA; McMahon-Tobin G; Hembrough T; Wang Y; Alcaraz AA; Leandro-García LJ; Rodríguez-Antona C; Snyder JP; Lavallee TM; Giannakakou P Cell Cycle; 2009 Dec; 8(23):3914-24. PubMed ID: 19901556 [TBL] [Abstract][Full Text] [Related]
2. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056 [TBL] [Abstract][Full Text] [Related]
3. Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions. Liaw TY; Salam NK; McKay MJ; Cunningham AM; Hibbs DE; Kavallaris M Mol Cancer Ther; 2008 Oct; 7(10):3150-9. PubMed ID: 18852118 [TBL] [Abstract][Full Text] [Related]
4. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404 [TBL] [Abstract][Full Text] [Related]
5. 2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells. Bhati R; Gökmen-Polar Y; Sledge GW; Fan C; Nakshatri H; Ketelsen D; Borchers CH; Dial MJ; Patterson C; Klauber-DeMore N Cancer Res; 2007 Jan; 67(2):702-8. PubMed ID: 17234781 [TBL] [Abstract][Full Text] [Related]
9. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. Brahn E; Banquerigo ML; Lee JK; Park EJ; Fogler WE; Plum SM J Rheumatol; 2008 Nov; 35(11):2119-28. PubMed ID: 18792999 [TBL] [Abstract][Full Text] [Related]
10. Estradiol dimer inhibits tubulin polymerization and microtubule dynamics. Jurášek M; Černohorská M; Řehulka J; Spiwok V; Sulimenko T; Dráberová E; Darmostuk M; Gurská S; Frydrych I; Buriánová R; Ruml T; Hajdúch M; Bartůněk P; Dráber P; Džubák P; Drašar PB; Sedlák D J Steroid Biochem Mol Biol; 2018 Oct; 183():68-79. PubMed ID: 29803726 [TBL] [Abstract][Full Text] [Related]
11. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. James J; Murry DJ; Treston AM; Storniolo AM; Sledge GW; Sidor C; Miller KD Invest New Drugs; 2007 Feb; 25(1):41-8. PubMed ID: 16969706 [TBL] [Abstract][Full Text] [Related]
12. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Chua YS; Chua YL; Hagen T Mol Cancer Ther; 2010 Jan; 9(1):224-35. PubMed ID: 20053769 [TBL] [Abstract][Full Text] [Related]
13. Targeting an Old Foe for Cancer: A Molecular Dynamics Perspective to Unravel the Specific Binding Nature of 2-Methoxy Estradiol to Human β-Tubulin Isotypes. Kumari S; Sobhia ME J Chem Inf Model; 2024 May; 64(10):4121-4133. PubMed ID: 38706255 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720 [TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Dahut WL; Lakhani NJ; Gulley JL; Arlen PM; Kohn EC; Kotz H; McNally D; Parr A; Nguyen D; Yang SX; Steinberg SM; Venitz J; Sparreboom A; Figg WD Cancer Biol Ther; 2006 Jan; 5(1):22-7. PubMed ID: 16357512 [TBL] [Abstract][Full Text] [Related]
16. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Mabjeesh NJ; Escuin D; LaVallee TM; Pribluda VS; Swartz GM; Johnson MS; Willard MT; Zhong H; Simons JW; Giannakakou P Cancer Cell; 2003 Apr; 3(4):363-75. PubMed ID: 12726862 [TBL] [Abstract][Full Text] [Related]
17. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents. Tangutur AD; Kumar D; Krishna KV; Kantevari S Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738 [TBL] [Abstract][Full Text] [Related]
18. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Bu SZ; Huang Q; Jiang YM; Min HB; Hou Y; Guo ZY; Wei JF; Wang JW; Ni X; Zheng SS Apoptosis; 2006 Mar; 11(3):413-25. PubMed ID: 16538384 [TBL] [Abstract][Full Text] [Related]
19. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478 [TBL] [Abstract][Full Text] [Related]
20. 2-Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways. Ting CM; Lee YM; Wong CK; Wong AS; Lung HL; Lung ML; Lo KW; Wong RN; Mak NK Biochem Pharmacol; 2010 Mar; 79(6):825-41. PubMed ID: 19883629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]